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Laboratory assaysDirect oral anticoagulant therapies, including direct anti-Xa and thrombin inhibitors have recently been intro-
duced and may have advantages over vitamin K antagonists such as warfarin. This review describes brieﬂy the
clinical utility andmechanism of action of these agents. Detailed information is provided on effect of these agents
on routine assays including the APTT and PT as well as their impact on specialty laboratory assays. Also included
are the use of drug speciﬁc assays and a discussion of alternative methods to determine relative drug concentra-
tion, such as evaluating drug calibrators in APTT and PT assays and using heparin calibrated anti-Xa assays to
measure direct Xa inhibitors.
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Oral anticoagulant agents recently approved in both theUnited States
(US) and Europe include dabigatran etexilate (Pradaxa®, Boehringer-
IngelheimPharma GmbH & Co., Ingelheim, Germany), rivaroxaban
(Xarelto® - Janssen and Bayer HealthCare), apixaban (Eliquis, Bristol-
Myers Squibb/Pﬁzer), and edoxaban (Savaysa, Daiichi Sankyo, Inc).
Dabigatran is a direct inhibitor of thrombinwhile rivaroxaban, apixaban,
and edoxaban are direct inhibitors of activated factor X (FXa). This new90 Upland Dr., Englewood CO
568 4314.
. This is an open access article underclass of anticoagulants has been referred to as non-vitamin K or novel
oral anticoagulants (NOACs), target-speciﬁc oral anticoagulant agents
(TSOACs), or direct oral anticoagulant agents (DOACs). The International
Society for Thrombosis and Haemostasis (ISTH) Scientiﬁc and Standard-
ization Committee (SSC) for the control of anticoagulation recommends
the term DOACs [1].
The most common clinical indications for these rapid-acting
anticoagulant drugs includes stroke prevention in non-valvular atrial
ﬁbrillation, thromboprophylaxis in hip or knee replacement surgery,
and for the treatment aswell as secondary prevention of venous throm-
boembolic disease (VTE), including deep venous thrombosis and
pulmonary embolus. It is estimated that 3 million individuals in the
US suffer atrial ﬁbrillation, as many as 900,000 could be affected withthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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knee replacement yearly [2–4]. In clinical trials, DOACs been shown to
be at least as effective aswarfarin, but with a reduced incidence of intra-
cranial hemorrhage [5–10]. As each of these agents has predictable
pharmacodynamics, pharmacokinetics and wide therapeutic windows,
routine therapeutic monitoring is not required [9,11]. Although thera-
peutic ranges have not been validated by the pharmaceutical companies
that manufacturer DOACs, information about drug concentration is
available in select FDA summary reports and some published studies
[12–16].
DOACs are rapidly-acting, target-speciﬁc anticoagulants that inhibit
both free and bound activated serine proteases, unlike heparin that
can inhibit only free proteases [17,18]. This is of clinical importance be-
cause bound thrombin and FXa retain activity. For example, activated
factor X (FXa) within the prothrombinase complex (bound FXa) is
300,000 fold more efﬁcient in converting prothrombin to thrombin,
than is circulating (free) FXa. The ability to inactivate bound serine pro-
teases makes the anticoagulant action of DOACs more robust than war-
farin or heparin. DOACs have relatively short half- lives and multiple
clearance mechanisms including both hepatic and renal clearance,
although dabigatran is cleared exclusively through the kidneys. Given
the many advantages of DOACS, their use may be favored over both
warfarin and heparin and it is likely that over time DOACs will be pre-
scribed to millions of patients annually [10].
Laboratory Assays and DOACS - An Overview
DOACs present unique challenges with both routine screening as
well as specialty assays of coagulation, and, although routinemonitoring
is not required, drug speciﬁc assays to measure plasma concentration
are available. Effect on routine and specialty assays as well as assays to
monitor DOACs will be discussed in subsequent sections.
Routine coagulation screening assays, including the prothrombin
time (PT), activated partial thromboplastin time (APTT), and thrombin
clotting time (TCT) are widely available on a routine and emergent
basis in most clinical laboratories. These assays are not a reliable mea-
sure of DOAC anticoagulant effect. This is because the sensitivity of the
PT and APTT varies considerably based on reagents used, as well as
the speciﬁc DOAC being measured [19–24]. [Fig. 1] Given this, PT or
APTT results (in seconds), in the presence of a given concentration of
DOAC, cannot be standardized across laboratories [21–23]. Further-
more, because DOACs inhibit both free and bound serine proteases, a
given prolongation of the clotting time, such as PT in seconds, when a
patient is on warfarin, does not equate to the same level of anti-
coagulation when a patient has the same prolongation of PT but is on
a direct Xa DOAC [25]. Patients can be fully anticoagulated on apixaban
for example, with only a slight elevation of the PT [26]. The traditional
TCT is exquisitely sensitive to the presence of dabigatran, with evenRivaroxaban
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Fig. 1. Difference sensitivity of a single PT reagent (Neoplastin CI+, Diagnotisca Stago,
Parisppany, NJ) to anti-Xa DOAC enriched pooled normal plasma. (Edoxaban data
extrapolated from reference [15]; apixaban data unpublished observation DMA and RG,
January 2015).trough levels resulting in “no clot detected”with some reagent systems
[27]. Direct Xa DOACs will not prolong the TCT.
Although laboratory monitoring is not required when patients are
administered DOACs, there are several clinical situations where deter-
mination of the level of anticoagulation may be of value, such as a
patient experiencing hemorrhage or thrombosis, or requiring an emer-
gent surgical procedure while on therapy [19,20]. DOAC concentrations
can be accurately measured using a variety of laboratory methods [19,
20,23,28,29]. Mass spectrometry, when calibrated with each drug to
be measured, is considered the gold-standard method and demon-
strates good accuracy and precision over a broad concentration range
although this test is not widely available [28]. More rapid methods in-
cluding the dilute thrombin time, ecarin methods and chromogenic
anti-Xa assays are potentially suitable means to measure DOACs, but
must employ calibrators and controls speciﬁc for (or referenced against)
the DOAC being measured [19,20,22,28,30]. Despite their availability,
problems associated with existing assays used to quantitate DOACs in-
clude lack of: 1) FDA- approved DOAC calibrators or kits, 2) validated
expected therapeutic plasma concentrations, and 3) knowledge of
plasma concentrations associated with increased thrombotic or hemor-
rhagic risk. Furthermore, clot-based and chromogenic assays demon-
strate variation between instrument/reagent systems, and also lack
speciﬁcity [30,31].
If drug-speciﬁc assays are not available, it has been recommended
that the relative sensitivity of a laboratory’s PT and APTT to various
types and concentrations of DOACs be determined locally. To accom-
plish this, commercially available calibrator material speciﬁc for the
drug to be measured is assayed in the local laboratory against routine
APTT and PT assays. This practice has been proposed by both the British
Committee for Standards in Haematology (BCSH) as well as the Sub-
committee on Control of Anticoagulation of the Scientiﬁc and Standard-
ization Committee of the International Society on Thrombosis and
Haemostasis, although published studies verifying this practice were
not available when these recommendations were made [32,33]. We
used drug speciﬁc calibrators to assess PT and APTT DOAC sensitivity
and compared this to sensitivity determined using well-characterized
patients samples with drug concentrations measured by LC/MS-MS.
With the exception of manufactured dabigatran calibrator evaluated
using 2 APTT reagents (SynthASil and PTT-A), the use of drug-speciﬁc
calibrators over-estimated reagent sensitivity compared to sensitivity
determined using patients samples [34]. A patient’s level of anti-
coagulation may be greatly underestimated when response to APTT
and/or PT is based on a manufacturer’s calibrator rather than samples
from patients actually on drug. [Fig. 2A-C] This discrepancy likely
reﬂects variation in the citrate concentration of the manufactured
calibrators compared to that used for APTT and PT assays or may be
due to the lyophilization process applied to the calibrator material.
Other laboratory methods, such as thromboelastographic measure-
ments or endogenous thrombin potential assays have also been ex-
plored in patients taking DOAC, but their clinical use is not widely
appreciated [20,35].
Dabigatran – Routine Screening Assays
The APTT is more responsive to dabigatran than is the PT while the
TCT is exquisitely responsive. The APTT, however, cannot reliably distin-
guish therapeutic from subtherapeutic levels of dabigatran. In a study
evaluating 7 APTT reagents (including 2 of the most common reagents
used in the US, Actin FS and SynthasIL), we demonstrated that 18% of
patients had a normal APTT despitemeasureable on-therapy dabigatran
levels using LC-MS/MS [27]. This ﬁnding does not support the rec-
ommendation in the “Practice Guide” from the American Society of
Hematology adapted in part from the American College of Chest Physi-
cians Evidence-Based Clinical Practice Guideline on Antithrombotic
and Thrombolytic Therapy (9th Edition), which states that in a patient
on dabigatran who is bleeding, “a normal APTT is an indicator that
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Fig. 2. A-C: Comparison of using commercial DOAC drug speciﬁc calibrators (open
squares) versus samples (open triangles) from patients taking these dabigatran (2A)
or rivaroxaban (2B-C) for determining reagent sensitivity for PT and APTT. The use of
calibrators tended to over estimate the sensitivity of both dabigatran (2A) and rivaroxaban
(2C) for Actin FSL (Siemens Healthcare Diagnostics, Newark, DE), and overestimated
the sensitivity of Innovin (Siemens) for PT testing (2B) when used on the ACL TOP700
(Instrumentation Laboratory, Bedford, MA).
Table 1
The effect of DOACs on routine and specialty coagulation assays.
Assay Direct Thrombin
Inhibitor
Direct Xa
Inhibitor §
APTT Prolonged ↑↑ Prolonged ↑¥
PT/INR Prolonged ↑ Prolonged ↑↑#
TCT Prolonged ↑↑↑ No effect
Clauss Fibrinogen No effect or
factitiously low¶
No effect
AT Activity
a. FXa based a. No effect a. Factitiously
overestimated
b. FIIa based b. Factitiously
overestimated
b. No effect
PC Activity
a. Clot based a. Factitiously
overestimated
a. Factitiously
overestimated
b. Chromogenic b. No effect b. No effect
PS Activity
a. Clot based a. Factitiously
overestimated
a. Factitiously
overestimated
b. Free PS Ag b. No effect b. No effect
APTT-based APCR with added
FV deﬁcient plasma
Factitiously
elevated ratio
Factitiously
elevated ratio
APTT- based factor assays,
one stage
Factitiously
low FVIII, IX, XI
Factitiously
low FVIII, IX, XI†#
PT- based factor assays,
one stage
Factitiously
low FII, V, VII, X†
Factitiously
low FVII, X, V, II#
Chromogenic FVIII activity No effect Factitiously low
APTT Mixing Study Incomplete correction Incomplete correction
PT Mixing Study Incomplete correction Incomplete correction
LA Tests Possible to misclassify
as LA
Possible to misclassify
as LA
APTT-activated partial thromboplastin time, PT/INR-prothrombin time/international
normalized ratio, AT-antithrombin, PC-protein C, PS-protein S, APCR-activated protein C
resistance, F-factor, LA-lupus anticoagulant.
↑ Slight increase in clotting time; ↑↑ moderate increase in clotting time; ↑↑↑ marked
increase in clotting time.
¶ Effect is method-dependent, most ﬁbrinogen assays show no effect.
† When drug levels are supratherapeutic.
§ Assay effect due to edoxaban is hypothesized based on drug action.
# The potential for demonstrating effect is reagent dependent.
¥ Apixaban has little to no effect on the APTT.
9D.M. Adcock, R. Gosselin / Thrombosis Research 136 (2015) 7–12dabigatran would be unlikely to contribute to bleeding” [36]. Further-
more we demonstrated that, depending on reagent used, 15 to 35% of
patients with plasma dabigatran levels N100 ng/mL had a normal
APTT, which is at variance with the British Committee for Standards
in Haematology guidance which states that “above 100 ng/mL, the
APTT is invariably prolonged” [32,33]. The thrombin time is exquisitely
responsive to dabigatran andwe demonstrated that a normal throm-
bin time indicates no or minimal plasma dabigatran levels are present
[27,37].
Dabigatran – Drug Speciﬁc Assays
Dabigatran plasma concentration can be assessed using a variety
of assays including; a dilute thrombin time (HEMOCLOT THROMBIN
INHIBITORS [Hyphen BioMed, France], an ecarin clotting time (Ecarin
Reagent, Diagnostica Stago, Asnieres France) or ecarin chromogenic
assay (ECA-T Kit; Diagnostica Stago, Asnieres, France), as long as eachassay employs a speciﬁc dabigatran standard curve [19,20,22,23,32,38,
39]. In a multicenter study, each assay demonstrated a linear relation-
ship with drug concentration determined by LC/MS-MS, although accu-
racy was questionable as the measured dabigatran levels varied in a
statistically signiﬁcant manner, even when the same method was used
by different laboratories [40].
Dabigatran - Interference in Specialty Coagulation Assays
Dabigatran will interfere with most APTT-based and some PT-based
assays, depending on the drug concentration. Only very high dabigatran
levels cause PT-based assay interference. Dabigatran interference in lab-
oratory testing produces factitious results that are not representative of
its physiologic effects. (Table 1) In a published study using dabigatran
spiked into normal plasma, we demonstrated that relatively low levels
of dabigatran (i.e. at 75 ng/mL which is below the typical on therapy
range) yield mixing study results consistent with an APTT inhibitor
and relatively high levels of dabigatran (i.e. at 200 ng/mL which is the
higher end of the therapeutic range) will cause inhibitor effect in the
PT as well as the APTT assay [41]. Surprisingly, further prolongation of
the mix was evident with incubation suggesting the presence of a
time and temperature-dependent inhibitor. APTT-based factor assays,
speciﬁcally factors VIII, IX, and XI can show signiﬁcant factitious de-
creases in activity due to dabigatran effect, depending on the concentra-
tion present. (Table 1) In our study, at dabigatran concentrations of 200
to 300 ng/mL factor VIII activity fell below10 IU/dL anddrug effect could
not be diluted out to achieve normal factor levels, and a Bethesda titer
Rivaroxaban
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Fig. 3. Sensitivity of low molecular weight calibrated Liquid Heparin assay to rivaroxaban
and apixaban using drug enriched normal pooled plasma samples. This method could
potentially be used to exclude signiﬁcant levels of direct Xa DOACs.
10 D.M. Adcock, R. Gosselin / Thrombosis Research 136 (2015) 7–12was measurable. This effect may occur with other APTT-based factor
assays, including factor IX and factor XI activity assays [41,42]. There-
fore, APTT-based screening tests, mixing studies, factor activity analysis,
and even Bethesda assays may yield spurious results in the presence
of dabigatran, leading to a false impression of either a factor deﬁciency,
or the presence of a speciﬁc factor inhibitor [29,41]. Clot-basedmethods
for protein C, protein S, and APC resistance are signiﬁcantly affected by
even small amounts of dabigatran, resulting in factitious overestimation
of protein C and protein S activities and a falsely elevated APC resistance
ratio. The reptilase time, also a clot-based assay similar in methodology
to the thrombin time, is not affected by dabigatran. FXa–based anti-
thrombin assays are unaffected by the presence of dabigatran, but a
factor IIa–based assay factitiously overestimates antithrombin concen-
tration. Dabigatran may cause false positive lupus anticoagulant (LA)
results but will not affect ELISA-based antiphospholipid assays [41,43].
Chromogenic or latex immunoassays including plasminogen activity,
quantitative D-dimer, free protein S antigen, chromogenic protein C ac-
tivity, vonWillebrand factor antigen, and vonWillebrand factor activity
(ristocetin cofactor), are not affected by the presence of dabigatran
[41–43]. Laboratorieswith limited access to patient information (eg, ref-
erence laboratories)may require amechanism (e.g. by performing TCT)
to rule out presence of dabigatran in order to avoidmisinterpretation of
laboratory results.
Anti-Xa DOACs- Routine Screening Assays
While overall, PT reagents aremore responsive to anti-XaDOACs in a
concentration-dependent manner than APTT reagents, the response
varies by speciﬁc anti-Xa DOAC and PT reagent used [19,20,22,24,26,
40]. [Fig. 1] For example, therapeutic levels of apixaban demonstrate
essentially no effect on APTT and little effect on PT assays, rivaroxaban
or edoxaban that often elevate both the APTT and PT [41–50]. Given a
similar mechanism of action between these agents, the basis for this
difference is unknown. APTT and uncalibrated PT of unknown respon-
siveness cannot reliably determine DOAC concentration. In a study of
patients on rivaroxaban 32% of the patient samples demonstrated a nor-
mal PT with “on therapy” plasma levels of drug [47]. As such, a normal
PT should not be used to signify that most or all of rivaroxaban has
been cleared. Some reagents are sufﬁciently responsive to rivaroxaban
(and possibly edoxaban) such that they can be used to measure drug
concentration if used with drug-speciﬁc calibrators [44].
Direct Anti-Xa DOAC – Drug Speciﬁc Assays
Direct anti-Xa DOACs can be accurately measured using modiﬁed
chromogenic anti-Xa assays that employ drug speciﬁc calibrators al-
though there are no FDA-approved kits available [22,23,31,40,45,51].
This same methodology is used to measure indirect FXa inhibitor
drugs including heparin, LMWH and fondaparinux. Contrary to popular
belief, the use of a drug-speciﬁc calibrator does not limit or improve the
assay’s speciﬁcity to that particular drug. All direct and indirect FXa in-
hibitor drugswill be detected in a chromogenic anti-Xa assay regardless
of the calibrator used. Quantifying direct Xa inhibitors agents with an
assay calibrated with UFH, LMWH or fondaparinux is not recommend-
ed, although these methods have the potential to exclude the presence
of DOACs at signiﬁcant concentration [23,31]. [Table 1; Fig. 3] While
these heparin-calibrated anti-Xa measurements have a linear relation-
ship to anti-Xa DOAC concentration, signiﬁcant limitations exist using
thesemethods to quantify anti-XaDOACs, speciﬁcally; 1) assays tomea-
sure indirect Xa inhibitors are measured in IU/mL and direct Xa DOACs
are measured in ng/mL and there is no direct relationship between
these units of measure, 2) there is signiﬁcant variability in measured
drug concentration, as demonstrated with rivaroxaban, between differ-
ent manufactured anti-Xa kits, 3) the therapeutic range, at least for
apixaban and rivaroxaban, far exceeds the typical calibration range for
UFH or LMWH and is often in the 5 – 9 IU/mL range and 4) the assayis not speciﬁc for anti-Xa DOACS and will detect all anti-Xa anticoagu-
lants [23,31]. Furthermore the lower limits of detection for these assays
varies with the calibrators used and some UFH or LMWH calibrated
anti-Xa assays may underestimate the level of drug present. [Table 2]
None-the-less, some heparin calibrated anti-Xa assays may have sufﬁ-
cient lower limits of quantitation to determine that rivaroxaban concen-
tration is 5 ng/mL or lower and therefore can be used to evaluate
patients prior to an intervention, such as surgery or the use of thrombo-
lytics [31,52]. The use of a high phospholipid dRVVT assay calibrated
with the speciﬁc drug to be measured may also be an alternative
means for quantifying anti-FXa DOACs [30,48].Anti-Xa DOAC - Interference in Special Coagulation Assays
Effect of rivaroxaban and apixaban on non-routine coagulation
assays has been demonstrated in our laboratories and is also based
on published literature [26,29,42,43]. The effect of edoxaban on spe-
cialty assays is not as well studied but is expected to mirror that of
rivaroxaban. Rivaroxaban and edoxaban prolong the PT to a greater de-
gree than the APTT and these agents may interfere with PT-based factor
activity assays (FVII, X, V, and II) causing factitiously low activities with
increasing drug concentration [29,42,43]. (Table 1) A normal plasma
mixing study leads to incomplete correction and may mimic a speciﬁc
inhibitor of FVII, X, V or II even though this effect is spurious. [29,43].
Apixaban has little effect on PT-based factor assays, even at a spiked
dose of 400 ng/mL [DMA and RG unpublished observations, January
2015.] Clot-based protein C and protein S activity and APCR results are
factitiously over-estimated in the presence of either rivaroxaban or
apixaban. ([29,43], DMA and RG unpublished observations, January
2015) A FXa–based antithrombin activity assay will be over-estimated
in the presence of direct Xa DOACs, but factor IIa–based assays are
not affected. DOACs may factitiously and signiﬁcantly decrease FVIII
chromogenic activity. ([29,43], DMA and RG unpublished observations,
January 2015) Direct Xa DOACS may cause false positive LA results
(even when the APTT is normal) but will not affect ELISA-based
antiphospholipid assays. ([43], DMA and RG unpublished observations,
January 2015) This contradicts other published studies demonstrating
that apixaban does not cause false positive LA results [45]. Other testing
platforms, such as select chromogenic or latex immunoassays, including
plasminogen activity, quantitative D-dimer, free protein S antigen, chro-
mogenic protein C activity, von Willebrand factor antigen, and von
Willebrand factor activity, are not affected by the presence of anti-Xa
DOACs [29,42,43]. Laboratories without sufﬁcient patient clinical and
medication history (eg, reference laboratories) may require a pre-test
algorithm to determine the suitability of samples for coagulation testing
(e.g. screening chromogenic anti-Xa).
Table 2
Comparison of different chromogenic methods for the measuring anti-Xa activity of rivaroxaban using either unfractionated heparin (UFH), low molecular weight heparin (LMWH) or
hybrid calibration. The LLQ (lower limit of quantitation)would determine the lowest amount rivaroxaban (asmeasured by tandemmass spectrometry) that could bemeasured, whereas
the ULQ (upper limit of quantitation) would ascertain the highest amount of rivaroxaban that could be measured with the respective calibration types.
Manufacturer
Reagent
Calibrator source LLQ
Anti-Xa U/mL
Lowest Rivaroxaban
level with LLQ
ULQ
Anti-Xa U/mL
Highest Rivaroxaban
level with ULQ
Chromogenix COAMATIC UFH 0.03 ~15 ng/ML 1.0 N200 ng/mL
Siemens Berichrom® UFH 0.03 ~10 ng/mL 1.05 N250 ng/mL
Stago STA® Liquid Heparin UFH 0 b5 ng/mL 0.60 ~24 ng/mL
Chromogenix COAMATIC LMWH 0.03 ~35 ng/mL 1.00 N200 ng/mL
Stago STA® Liquid Heparin LMWH 0 b5 ng/mL 1.82 ~70 ng/mL
Stago STA® Liquid Heparin Hybrid 0 b5 ng/mL 1.86 ~80 ng/mL
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While DOACs do not require routine laboratory monitoring, they
may have signiﬁcant impact on the clinical laboratory. The need to
assess these drugs in emergent situations as well as their impact on
routine and specialty coagulation assays has created challenges in
most laboratories. Differences in the sensitivity of routine coagulation
screening tests to DOACs prevent their use in reliably determining
drug concentration. While commercially available, the lack of FDA
approved calibrators or methods for quantifying DOACs have created
a general reluctance to implement quantitative assays. Alternative
methods for estimating drug concentration or the use of tests that can
exclude signiﬁcant amounts of DOACs, including the TCT and heparin
anti-Xa chromogenic assay may be of clinical value. Use of commercial
calibrators to assess reagent sensitivity to DOACs should be used with
caution, especially when assessing direct FXa DOACs. While it is best
to avoid performance of specialty coagulation assays for patients
on DOACs, correct interpretation of results that are performed in the
presence of DOACs is necessary to prevent a misleading diagnosis and
subsequent intervention. For patients on DOACs, the results from coag-
ulation assays should be used in conjunction with their clinical presen-
tation when assessing bleeding or thrombotic risk.
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